Intravenous moxifloxacin launched

Bayer Schering has launched an intravenous preparation of moxifloxacin, Avelox, for the treatment of community acquired pneumonia and complicated skin and skin structure infections.

Moxifloxacin should only be given when it is considered inappropriate to use antibacterial agents that are commonly recommended and it should be used in accordance with local antibiotic guidelines.

Initial intravenous treatment may be followed by oral therapy when considered clinically appropriate; the recommended total duration of treatment is 7–21 days depending on the infection.

View Avelox IV drug record

Further information: Bayer Schering

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in